Gleason grade progression is uncommon (Q37177744)

18 August 2017

Gleason grade progression is uncommon (English)

1 reference

18 August 2017

11

Lorelei A Mucci

1 reference

18 August 2017

10

Massimo Loda

1 reference

18 August 2017

2

Meir J Stampfer

1 reference

18 August 2017

Kathryn L Penney

1

1 reference

18 August 2017

Jaquelyn L Jahn

3

1 reference

18 August 2017

Jennifer A Sinnott

4

1 reference

18 August 2017

Richard Flavin

5

1 reference

18 August 2017

Jennifer R Rider

6

1 reference

18 August 2017

Stephen Finn

7

1 reference

18 August 2017

Edward Giovannucci

8

1 reference

18 August 2017

Howard D Sesso

9

1 reference

18 August 2017

Michelangelo Fiorentino

12

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 August 2013

1 reference

18 August 2017

1 reference

18 August 2017

73

1 reference

18 August 2017

5163-5168

1 reference

18 August 2017

16

1 reference

Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775342

Clonal progression of prostate cancers from Gleason grade 3 to grade 4.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775342

Do Gleason patterns 3 and 4 prostate cancer represent separate disease states?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775342

Prostate cancer staging and grading at radical prostatectomy over time.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775342

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775342

Stage shift in PSA-detected prostate cancers - effect modification by Gleason score

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775342

Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775342

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775342

Epidemiology of prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775342

Final report on the aspirin component of the ongoing Physicians' Health Study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775342

Change in prostate cancer grade over time in men followed expectantly for stage T1c disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775342

Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775342

PSA-detected prostate cancer and the potential for dedifferentiation--estimating the proportion capable of progression

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775342

Prostate cancer and the Will Rogers phenomenon.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775342

Natural History of Early, Localized Prostate Cancer

3 September 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775342

20 October 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775342

Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease

4 December 2018

1 reference

12 December 2020

Continuing trends in pathological stage migration in radical prostatectomy specimens

1 reference

12 December 2020

Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration

1 reference

12 December 2020

Evidence to support a continued stage migration and decrease in prostate cancer specific mortality

1 reference

12 December 2020

How Well Does the Gleason Score Predict Prostate Cancer Death? A 20-Year Followup of a Population Based Cohort in Sweden

1 reference

12 December 2020

Gleason score, age and screening: Modeling dedifferentiation in prostate cancer

1 reference

12 December 2020

How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer?

1 reference

12 December 2020

Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer

1 reference

12 December 2020

Original Gleason system versus 2005 ISUP modified Gleason system: the importance of indicating which system is used in the patient's pathology and clinical reports

1 reference

12 December 2020

Lead-time in the European Randomised Study of Screening for Prostate Cancer

1 reference

12 December 2020

10.1158/0008-5472.CAN-13-0427

Identifiers

DOI

1 reference

18 August 2017

1 reference

18 August 2017

1 reference